Literature DB >> 14727257

Genetic defects leading to hereditary thrombotic thrombocytopenic purpura.

Koichi Kokame1, Toshiyuki Miyata.   

Abstract

In patients with thrombotic thrombocytopenic purpura (TTP), unusually large multimers of von Willebrand factor (VWF) circulate in the plasma. This is caused by a functional deficiency of VWF-cleaving protease, ADAMTS-13. Although TTP usually occurs as an acquired form due to autoantibodies against ADAMTS-13, the condition may be inherited in an autosomal recessive fashion. Thus far, genomic DNA from 23 patients with hereditary TTP and their families has been analyzed and 33 causative mutations identified in the ADAMTS13 gene: 19 missense, five nonsense, five frameshift, and four splice mutations. Common missense polymorphisms have been also found, one of which significantly reduces ADAMTS-13 activity. No cases have been found without mutations in the ADAMTS13 gene, suggesting that genetic defects in ADAMTS13 are the dominant cause of hereditary TTP. Further analysis may reveal the genetic background associated with acquired TTP and other thrombotic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727257     DOI: 10.1053/j.seminhematol.2003.10.002

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  12 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 3.  Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation.

Authors:  Toshiyuki Miyata; Rina Kimura; Yoshihiro Kokubo; Toshiyuki Sakata
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 4.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 5.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 6.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

7.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

8.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05

9.  The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.

Authors:  Ping Zhang; Weilan Pan; Ann H Rux; Bruce S Sachais; X Long Zheng
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

10.  Thrombotic microangiopathy in haematopoietic cell transplantation: an update.

Authors:  Evi Stavrou; Hillard M Lazarus
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-03       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.